Viking Therapeutics Inc. (VKTX)
Viking Therapeutics: Still Cheap, But Watch Double Top
Viking Therapeutics is advancing its GLP-1 weight-loss pipeline, with Phase 3 trials progressing and oral formulation development accelerating. The consensus analyst price targets average $92.58, suggesting substantial upside. Recent biotech sector M&A highlights VKTX's potential valuation in a rapidly expanding GLP-1 market.
Buyout Buzz Around VKTX Is Back: What's Fueling the Speculation?
Viking Therapeutics' expanding obesity pipeline and upcoming VK2735 data reignite buyout speculation as investors weigh its growing strategic appeal.
Why Viking Therapeutics, Inc. (VKTX) Dipped More Than Broader Market Today
Viking Therapeutics, Inc. (VKTX) closed the most recent trading day at $39.97, moving 5.13% from the previous trading session.
How Much Could $1,000 Invested in Viking Therapeutics Be Worth by 2030?
Viking Therapeutics could have a medicine on the market within two years. To capture market share, the new offering will need to fight a pair of pharma juggernauts.
Viking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know
In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $37.48, denoting a -3.92% move from the preceding trading day.
Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Viking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know
In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $36.97, denoting a -2.38% move from the preceding trading day.
VKTX Stock Jumps on Phase I Study Initiation for New Obesity Drug
Viking Therapeutics jumps after it starts its first human study of VK3019, expanding its obesity pipeline with a second candidate alongside its lead program, VK2735.
Viking Therapeutics, Inc. (VKTX) Gains As Market Dips: What You Should Know
In the most recent trading session, Viking Therapeutics, Inc. (VKTX) closed at $30.29, indicating a +2.16% shift from the previous trading day.
Viking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to Know
In the latest trading session, Viking Therapeutics, Inc. (VKTX) closed at $27.73, marking a -5.13% move from the previous day.
Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider
The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $29.78, representing a +1.53% change from its previous close.
Viking Therapeutics, Inc. (VKTX) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Viking Therapeutics, Inc. (VKTX) Presents at Jefferies Global Healthcare Conference 2026 Transcript
